Jim Simons
FDMT icon

Jim Simons’s 4D Molecular Therapeutics FDMT Stock Holding History

Jim Simons’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.17M Buy
614,573
+36,308
+6% +$354K 0.01% 1168
2026
Q1 		$5.38M Buy
578,265
+65,365
+13% +$569K 0.01% 1339
2025
Q4 		$3.85M Buy
512,900
+199,714
+64% +$2.03M 0.01% 1464
2025
Q3 		$2.72M Buy
313,186
+196,633
+169% +$1.18M ﹤0.01% 1872
2025
Q2 		$432K Buy
116,553
+97,000
+496% +$341K ﹤0.01% 2909
2025
Q1 		$63.2K Buy
+19,553
New +$92.1K ﹤0.01% 3263
2024
Q2 		– Sell
-69,833
Closed -$2.22M – 3636
2024
Q1 		$2.22M Buy
+69,833
New +$1.78M ﹤0.01% 1964
2023
Q2 		– Sell
-13,800
Closed -$237K – 4032
2023
Q1 		$237K Sell
13,800
-114,300
-89% -$2.22M ﹤0.01% 3212
2022
Q4 		$2.84M Buy
128,100
+59,000
+85% +$911K ﹤0.01% 1856
2022
Q3 		$556K Sell
69,100
-190,500
-73% -$1.73M ﹤0.01% 2870
2022
Q2 		$1.81M Buy
259,600
+190,500
+276% +$1.85M ﹤0.01% 2261
2022
Q1 		$1.04M Buy
69,100
+24,300
+54% +$382K ﹤0.01% 2699
2021
Q4 		$983K Buy
+44,800
New +$1.1M ﹤0.01% 2653

Other funds holding FDMT

Jupiter Topco
Jupiter Topco New York $245B AUM
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Novo Holdings A/S
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Trails Edge Capital Partners
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Jim Simons's FDMT Position: Q2 2026 in Review

Jim Simons increased its 4D Molecular Therapeutics (FDMT) stake by 6.3% in Q2 2026, buying an estimated $354K and bringing the position to 614,573 shares worth $8.17M. The position accounts for 0.01% of the portfolio, ranked #1168.

Jim Simons first reported a position in FDMT in Q4 2021 and has held it in 13 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Jim Simons held 614,573 shares of 4D Molecular Therapeutics worth $8.17M as of Q2 2026.
  • Jim Simons bought 36,308 4D Molecular Therapeutics shares in Q2 2026, an estimated $354K.
  • 4D Molecular Therapeutics made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1168 holding.
  • Jim Simons first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.